Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Schrödinger (SDGR) Up +4.5% Over 30 Days Amid Sharp Swings

Schrödinger (SDGR) Up +4.5% Over 30 Days Amid Sharp Swings

Key Takeaways

  • Schrödinger (SDGR) shares rose roughly 4.5% over the trailing 30 days, but that modest net gain masked unusually wide intra-period swings.
  • The stock climbed above $33 before retreating toward the low-$20s mid-period, then rebounded sharply in recent sessions, underscoring elevated volatility.
  • As a physics-based computational chemistry and software platform, Schrödinger sits at the intersection of drug discovery and the broader artificial intelligence investment theme.
  • Recurring software licensing revenue and a growing drug-discovery collaboration pipeline remain central to the company’s long-term narrative.
  • Investors are closely watching software revenue growth, collaboration milestones, and the pace of AI adoption across pharmaceutical R&D.
  • Readers can explore additional details on Price Targets, Earnings, and Forecast on dedicated pages.
  • For automated trading insights, explore Trending AI Robots to see curated, top-performing algorithmic strategies.

A Look at Recent Trading Patterns

Schrödinger shares have traded in a wide range in recent weeks. Over the trailing 30 days, the stock moved from a closing level near $29.50 to an intraday price around $30.84, reflecting a net gain of approximately 4.5%. That headline number, however, tells only part of the story. The stock touched a multi-week peak above $33 in early October before pulling back to the low-$20s and then recovering, a pattern that points to shifting sentiment rather than a smooth directional trend.

The company’s positioning in computational drug discovery means its share price tends to respond to a mix of factors, including software revenue trends, collaboration announcements, and the broader appetite for AI-linked life sciences equities. Recent trading has been characterized by sharp single-session moves, suggesting that short-term positioning and sector rotation are playing a meaningful role alongside fundamentals. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Schrödinger’s Core Business and Competitive Position

Schrödinger is a scientific software and drug discovery company built on a physics-based computational platform. Its software applies molecular simulation and predictive modeling to evaluate candidate molecules, helping researchers narrow the search space in drug design and materials science. The platform is used by pharmaceutical, biotechnology, and materials companies to improve the speed and efficiency of discovery.

The business model combines recurring software licensing revenue with drug discovery collaborations and a proprietary pipeline of wholly owned and partnered programs. This dual structure gives the company exposure both to steady software demand and to longer-term, milestone-driven value creation. Within the competitive landscape, Schrödinger differentiates itself through the depth of its physics-based simulation capabilities, which complement the rapidly expanding use of machine learning and generative AI in life sciences research.

What’s Behind the Recent Price Action

The most visible driver of SDGR’s recent behavior has been volatility itself. After rallying above $33 in early October, the stock sold off into the low-$20s before rebounding. While no single company-specific event can be cited for every swing, several recurring themes appear relevant to investor sentiment.

First, Schrödinger’s software business remains closely tied to R&D spending cycles at pharmaceutical and biotechnology customers, making its revenue trajectory sensitive to broader sector budgets. Second, the company’s profile as a computational and AI-adjacent platform means its shares can move alongside the broader artificial intelligence and life sciences technology complex, which has experienced bouts of rotation. Third, collaboration and pipeline announcements, along with quarterly financial disclosures, typically serve as focal points for reassessing the stock’s valuation.

Because the recent move has been sharp in both directions, much of the near-term action appears driven by positioning and sentiment rather than a singular fundamental catalyst, reinforcing the importance of monitoring confirmed company disclosures over speculation. From what I see, tools like Tickeron’s AI Pattern Search Engine can help track these patterns more systematically.

2026 Outlook and What Investors Should Watch

Looking ahead, several factors are likely to shape the SDGR narrative. Software revenue growth and customer adoption remain foundational, as they reflect demand for computational tools across the pharmaceutical industry. Investors should also monitor collaboration and pipeline milestones, which can materially affect the company’s longer-term value trajectory. The pace at which AI and machine learning techniques are integrated into drug discovery workflows is another important theme, given Schrödinger’s positioning at that intersection.

Macroeconomic conditions, including interest rates and capital availability for biotechnology and life sciences companies, may influence both customer spending and the stock’s valuation. Competitive developments in computational chemistry and AI-driven discovery software also warrant attention. As with any high-volatility growth-oriented name, upcoming quarterly disclosures, management guidance, and analyst updates will be key checkpoints for validating the investment case. I’m watching this closely as the AI integration theme continues to evolve.

Using AI Tools for Deeper Insights

In my own research process, I’ve found value in combining fundamental analysis with systematic signals. Tickeron’s AI Trading Bots offer a way to explore automated strategies that can complement manual review of names like Schrödinger, providing an additional layer of data-driven perspective without replacing core due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SDGR

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for SDGR turns negative, indicating new downward trend

SDGR saw its Momentum Indicator move below the 0 level on November 17, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In 80 of the 90 cases, the stock moved further down in the following days. The odds of a decline are at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for SDGR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 27 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.

The Moving Average Convergence Divergence Histogram (MACD) for SDGR turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 37 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

SDGR moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SDGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for SDGR crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.

Following a +16.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where SDGR advanced for three days, in 215 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

SDGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 168 of 199 cases where SDGR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.781) is normal, around the industry mean (4.523). SDGR has a moderately low P/E Ratio (-40.849) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.835) is also within normal values, averaging (6.105).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SDGR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SDGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -13%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 2%. DRIO experienced the highest price growth at 5%, while LFMD experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 27%. For the same stocks of the Industry, the average monthly volume growth was 34% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -5 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of chemical simulation software solutions to pharmaceutical industry.

Industry ServicestotheHealthIndustry

Industry
N/A
Address
1540 Broadway
Phone
+1 212 295-5800
Employees
850
Web
https://www.schrodinger.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.
Schrödinger (SDGR) Up +4.5% Over 30 Days Amid Sharp Swings